图文详情
Telisotuzumab vedotin (ABBV-399), an antibody-drug conjugate (ADCs), targets c-Met and comprises the cytotoxic agent Monomethyl Auristatin E (MMAE), the Telisotuzumab antibody, and a cleavable mc-val-cit-PABC linker. This compound is utilized in cancer research [1].